[Development of combined drugs (ARB and diuretics)].
Arakawa
Kikuo
K
Fukuoka University.
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000494:pharmacology; D001562:Benzimidazoles; D001565:Benzoates; D001713:Biphenyl Compounds; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000494:pharmacology; D004338:Drug Combinations; D015195:Drug Design; D006801:Humans; D006852:Hydrochlorothiazide; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology; D007093:Imidazoles; D007687:Kidney Tubules, Proximal / Q000378:metabolism; D019808:Losartan; D000068557:Olmesartan Medoxomil; D017410:Practice Guidelines as Topic; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D012964:Sodium / Q000378:metabolism; D000077333:Telmisartan; D013777:Tetrazoles
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D001713:Biphenyl Compounds; D004232:Diuretics; D004338:Drug Combinations; D007093:Imidazoles; D013777:Tetrazoles; C436283:telmisartan, hydrochlorothiazide drug combination; D006852:Hydrochlorothiazide; D000068557:Olmesartan Medoxomil; D012964:Sodium; D019808:Losartan; C081643:candesartan; D000077333:Telmisartan